Dr. Ujjwal Neogi Research Lab
The Neogi Research lab aims to identify the molecular mechanism and identify novel biomarkers of natural immune control against viral diseases and immune aging. We aim to identify the components of the immune response that are required for natural immune protection and disease severity that can be translated into the future development of vaccine and antiviral strategies against emerging and re-emerging viruses like human immunodeficiency viruses (HIV), Crimean–Congo hemorrhagic fever (CCHF) viruses, dengue viruses, Zika viruses. Using multi-omics system biology approaches we are interested in understanding how virus rewires host cell metabolism to facilitate optimal viral replication. We combine unbiased multi-omics technologies (transcriptomics, proteomics and metabolomics) with hypothesis-driven approaches (based on our in vitro and ex vivo data) and amalgamate molecular biology, biochemistry, structural biology with advance cell culture system and analysis of patient material, to understand the antiviral defense, it’s association with disease severity and immune aging in viral diseases. It provides new possibilities for therapeutic modulation of immune responses, development of antivirals and vaccines and understands the mechanism of immune-aging in viral infections.
- To understand the mechanisms of natural control of HIV-1 replication by the group of HIV-positive individuals called Elite Controllers.
- To understand disease pathogenesis in hemorrhagic fever viruses including dengue viruses (DENV), chikungunya viruses (CHIKV), Zika viruses (ZIKV) Crimea Congo Hemorrhagic Fever Virus (CCHFV), and Ebola Viruses using system biology approaches.
- To understand how virus rewires host cell metabolism to facilitate optimal viral replication in HIV and SARS-CoV-2.
- To elucidate the underlying mechanism of immune-aging in people living with HIV with long term antiretroviral therapy.
- To elucidate the metabolic and immune signature on the aspect of metabolic syndrome (MestS) during HIV infection.
- To type the HIV drug resistance in major and minor viral quasispecies in low- and middle- income countries (South Africa, Cameroon, and India).